cfDNA as a Prognostic Marker of Response to Taxane Based Chemotherapy in Patients with Prostate Cancer

MLA

Daniel Porres, et al. “CfDNA as a Prognostic Marker of Response to Taxane Based Chemotherapy in Patients with Prostate Cancer.” Journal of Urology, vol. 194, Oct. 2015, pp. 966–71. EBSCOhost, https://doi.org/10.1016/j.juro.2015.04.055.

APA

Daniel Porres, Axel Heidenreich, David Pfister, & Alexandra Kienel. (2015). cfDNA as a Prognostic Marker of Response to Taxane Based Chemotherapy in Patients with Prostate Cancer. Journal of Urology, 194, 966–971. https://doi.org/10.1016/j.juro.2015.04.055

Chicago

Daniel Porres, Axel Heidenreich, David Pfister, and Alexandra Kienel. 2015. “CfDNA as a Prognostic Marker of Response to Taxane Based Chemotherapy in Patients with Prostate Cancer.” Journal of Urology 194 (October): 966–71. doi:10.1016/j.juro.2015.04.055.